Boucher Kelley 4
4 · Apellis Pharmaceuticals, Inc. · Filed Sep 3, 2025
Insider Transaction Report
Form 4
Boucher Kelley
Chief People Officer
Transactions
- Award
Common Stock
2025-09-02+30,476→ 97,658 total - Award
Stock Option (Right to Buy)
2025-09-02+45,766→ 45,766 totalExercise: $28.17Exp: 2035-09-02→ Common Stock (45,766 underlying)
Footnotes (2)
- [F1]This restricted stock unit was granted on September 2, 2025. The restricted stock unit will vest 25% annually over four years from grant date, subject to her continued service as an officer, or upon later termination of her service.
- [F2]This represents a stock option award granted September 2, 2025 that vests over a four-year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.